NCT04659343 TDM for Optimized Outcome in Patients With mRCC.
| NCT ID | NCT04659343 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Niels Fristrup |
| Condition | Kidney Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2020-11-01 |
| Primary Completion | 2028-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2020-11-01 with a primary completion date of 2028-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients. Furthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.
Eligibility Criteria
Inclusion Criteria: * Patients in Denmark with medically treated metastatic renal cell carcinoma. Exclusion Criteria: * No written informed consent.
Contact & Investigator
Niels Fristrup, MD, PhD
PRINCIPAL INVESTIGATOR
University of Aarhus
Frequently Asked Questions
Who can join the NCT04659343 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04659343 currently recruiting?
Yes, NCT04659343 is actively recruiting participants. Contact the research team at niels.fristrup@rm.dk for enrollment information.
Where is the NCT04659343 trial being conducted?
This trial is being conducted at Aarhus, Denmark.
Who is sponsoring the NCT04659343 clinical trial?
NCT04659343 is sponsored by Niels Fristrup. The principal investigator is Niels Fristrup, MD, PhD at University of Aarhus. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.